These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 23401433)

  • 41. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.
    Wang Y; Tian PW; Wang WY; Wang K; Zhang Z; Chen BJ; He YQ; Li L; Liu H; Chuai S; Li WM
    Oncotarget; 2016 Oct; 7(40):65208-65217. PubMed ID: 27564104
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice.
    Aggarwal C; Rolfo CD; Oxnard GR; Gray JE; Sholl LM; Gandara DR
    Nat Rev Clin Oncol; 2021 Jan; 18(1):56-62. PubMed ID: 32918064
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
    Dolly SO; Collins DC; Sundar R; Popat S; Yap TA
    Drugs; 2017 May; 77(8):813-827. PubMed ID: 28378229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
    Sousa AC; Silveira C; Janeiro A; Malveiro S; Oliveira AR; Felizardo M; Nogueira F; Teixeira E; Martins J; Carmo-Fonseca M
    Lung Cancer; 2020 Jan; 139():35-40. PubMed ID: 31715539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Personalized targeted therapy for lung cancer.
    Wu K; House L; Liu W; Cho WCS
    Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
    Canberk S; Engels M
    Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
    Passiglia F; Bronte G; Castiglia M; Listì A; Calò V; Toia F; Cicero G; Fanale D; Rizzo S; Bazan V; Russo A
    Expert Opin Biol Ther; 2015; 15(11):1553-66. PubMed ID: 26360115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
    Gerber DE; Oxnard GR; Govindan R
    Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
    Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Personalized therapy for non-small cell lung cancer: which drug for which patient?
    Villaruz LC; Socinski MA
    Semin Thorac Cardiovasc Surg; 2011; 23(4):281-90. PubMed ID: 22443647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.